Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...
Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...
3d
Zacks Investment Research on MSNMirum's Heavy Dependence on Livmarli for Revenues Remains a WoeMirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...
Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).
Dog and cat owners can have peace of mind knowing their animals are properly screened and protected as a result of advanced diagnostic tools.
Fleas – These small insects cause itching, discomfort ... and can spread serious illnesses such as tick bite fever and biliary. • Roundworms – These intestinal parasites can cause weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results